PDL BioPharma (TM) Incorporated, founded in 1986 and based in Fremont, California, employs its proprietary humanization technology platform in developing biopharmaceuticals that treat cancers, cardiovascular disease, inflammation, and autoimmune disorders. The firm is known for Cardene (R) I.V., Retavase (R), and IV Busulfex (R) products. Cardene I.V., approved by the U.S. Food and Drug Administration (FDA) in 1992, is an intravenous calcium channel blocker that supports the short-term treatment of hypertension. Retavase, approved by the FDA in 1996, is a fibrinolytic agent. It breaks down blood clots in coronary arteries, reducing damage associated with heart attacks. Bulsulfex, approved by the FDA in 1999, is a conditioning agent for chronic myelogenous leukemia patients who are undergoing bone marrow transplants. PDL BioPharma is developing a Crohn's disease product, Nuvion (R), which is in clinical trials. The firm also is developing asthma, multiple sclerosis, and multiple myeloma treatments. PDL BioPharma has collaborated with Genentech Incorporated, Roche, MedImmune Incorporated, Wyeth, and Biogen Idec. The firm's humanization platform has been used in developing Synagis (R), Herceptin (R), Avastin (R), Mylotarg (R), Xolair (R), Synagis, and other pharmaceuticals. PDL BioPharma serves customers across North America, Europe, and Asia. The firm is listed on NASDAQ under the PDLI symbol. The company was founded as Protein Design Labs Incorporated. It was renamed in 2006.